Trial intelligence / Profile preview

FAN study

2024-515377-10-00Phase 4Completed

Sponsor: Medical University of Graz
Start: Nov 2024
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 4, randomised, double-blind trial in exudative macular degeneration comparing Faricimab arm with Aflibercept arm (2 arms). Started Nov 2024; status: completed.

Drugs

faricimabaflibercept

Conditions

exudative macular degeneration

Beyond the preview

Go deeper on 2024-515377-10-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-515377-10-00.